Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

A Cheap Deworming Pill Could Help Beat Drug-Resistant Lung Cancer : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-13

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 2 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of four check out. One claim the study doesn't address.

  • 2 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedA new study in PLOS ONE suggests that the deworming medicine mebendazole may help beat drug-resistant lung cancer when combined with the targeted drug gefitinib.View evidenceHide evidence

Why this verdict

The abstract-level paper profile supports a preclinical combination effect: reduced viability in one gefitinib-resistant NSCLC cell line and tumor-growth suppression in an animal tumor model. But the headline-style wording that mebendazole may help “beat drug-resistant lung cancer” generalizes beyond the abstract evidence, which does not show clinical benefit, tumor elimination, or broad efficacy across lung cancers. The body caveats partly correct this, but the headline still outruns the evidence.

1

Study evidence

Gefitinib alone produced minimal cytotoxicity in HCC827 GR5 cells (viability 92.7 ± 1.5%), whereas MBZ alone reduced viability to 79.7 ± 0.6% at 0.1 µM and 29.7 ± 0.6% at 0.5 µM (p < 0.001). Combination treatment (gefitinib 1 µM + MBZ 0.1 µM) further reduced viability to 37.7 ± 0.6% (p < 0.001).Viability: gefitinib 92.7 ± 1.5%; MBZ 79.7 ± 0.6% (0.1 µM) and 29.7 ± 0.6% (0.5 µM); combination 37.7 ± 0.6% (gefitinib 1 µM + MBZ 0.1 µM).

“restore sensitivity to gefitinib in gefitinib-resistant HCC827 GR5 cells”
2

Study evidence

Gefitinib + MBZ combination significantly suppressed tumor growth compared with control, prolonging tumor doubling time from 6.2 days to 25 days and producing a growth delay of 18.8 days (p < 0.01).Doubling time: 6.2 → 25 days; growth delay: 18.8 days (p < 0.01)

“In vivo, combination therapy significantly suppressed tumor growth”
Claim 2 of 4Not coveredIn mice carrying tumors from the resistant human cells, the combination lengthened the median time for tumors to double in size compared with either single drug or no treatment.View evidenceHide evidence

As stated25 days with both drugs, versus 15.5 days with gefitinib alone, 10.3 days with mebendazole alone, and 6.2 days without treatment

Why this verdict

The abstract profile supports that the combination prolonged tumor doubling time from 6.2 days in controls to 25 days and suppressed tumor growth in vivo. However, the specific single-drug comparator doubling times stated in the story, and some model details such as tumors from the resistant human cells, are not provided at abstract depth. Those details may be in the full paper but are not verifiable from the supplied abstract-level profile.

1

Study evidence

Gefitinib + MBZ combination significantly suppressed tumor growth compared with control, prolonging tumor doubling time from 6.2 days to 25 days and producing a growth delay of 18.8 days (p < 0.01).Doubling time: 6.2 → 25 days; growth delay: 18.8 days (p < 0.01)

“In vivo, combination therapy significantly suppressed tumor growth”
Claim 3 of 4SupportedIn laboratory experiments, the mebendazole-gefitinib pairing reduced resistant cancer-cell viability more than either drug alone.View evidenceHide evidence

As statedabout 38% viability with the combination after 72 hours, versus about 93% with gefitinib alone and about 80% with low-dose mebendazole alone

Why this verdict

The in vitro viability numbers match the abstract profile: gefitinib alone left viability at 92.7 ± 1.5%, low-dose MBZ at 79.7 ± 0.6%, and gefitinib 1 µM + MBZ 0.1 µM reduced viability to 37.7 ± 0.6%. The claim accurately frames this as a laboratory result in resistant cells.

1

Study evidence

Gefitinib alone produced minimal cytotoxicity in HCC827 GR5 cells (viability 92.7 ± 1.5%), whereas MBZ alone reduced viability to 79.7 ± 0.6% at 0.1 µM and 29.7 ± 0.6% at 0.5 µM (p < 0.001). Combination treatment (gefitinib 1 µM + MBZ 0.1 µM) further reduced viability to 37.7 ± 0.6% (p < 0.001).Viability: gefitinib 92.7 ± 1.5%; MBZ 79.7 ± 0.6% (0.1 µM) and 29.7 ± 0.6% (0.5 µM); combination 37.7 ± 0.6% (gefitinib 1 µM + MBZ 0.1 µM).

“restore sensitivity to gefitinib in gefitinib-resistant HCC827 GR5 cells”
Claim 4 of 4SupportedThe article says the findings are preclinical, did not eliminate tumors, and cannot yet show that mebendazole fully restores gefitinib sensitivity or is safe and effective in people.View evidenceHide evidence

Why this verdict

The paper profile is explicitly preclinical, with evidence from one resistant cell-line model and an in vivo animal tumor study. It reports tumor-growth suppression rather than tumor elimination and provides no human efficacy or human safety evidence. The caveat that the study cannot yet establish full restoration of gefitinib sensitivity or human safety/effectiveness is consistent with the abstract-level limitations.

1

Study evidence

Gefitinib alone produced minimal cytotoxicity in HCC827 GR5 cells (viability 92.7 ± 1.5%), whereas MBZ alone reduced viability to 79.7 ± 0.6% at 0.1 µM and 29.7 ± 0.6% at 0.5 µM (p < 0.001). Combination treatment (gefitinib 1 µM + MBZ 0.1 µM) further reduced viability to 37.7 ± 0.6% (p < 0.001).Viability: gefitinib 92.7 ± 1.5%; MBZ 79.7 ± 0.6% (0.1 µM) and 29.7 ± 0.6% (0.5 µM); combination 37.7 ± 0.6% (gefitinib 1 µM + MBZ 0.1 µM).

“restore sensitivity to gefitinib in gefitinib-resistant HCC827 GR5 cells”
2

Study evidence

Gefitinib + MBZ combination significantly suppressed tumor growth compared with control, prolonging tumor doubling time from 6.2 days to 25 days and producing a growth delay of 18.8 days (p < 0.01).Doubling time: 6.2 → 25 days; growth delay: 18.8 days (p < 0.01)

“In vivo, combination therapy significantly suppressed tumor growth”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Animal tolerability finding: the abstract reports antitumor effects without substantial systemic toxicity, but does not provide detailed toxicity methods or quantitative safety data.

    The story emphasizes that human safety and effectiveness are unproven, which is appropriate, but it does not clearly reflect the paper’s reported animal tolerability result or the abstract’s lack of detail on how toxicity was assessed.

    From in_vivo_animal

  • Secondary mechanism finding: MBZ and the combination were linked to replication-associated DNA damage/stress markers, including comet assay damage and γ-H2AX activation.

    The presented story claims focus on viability, tumor growth, and preclinical caveats; they do not mention the mechanistic DNA-damage experiments.

    From in vitro DNA damage assays (HCC827 GR5)

3 things the story did carry across
  • Primary in vitro efficacy finding: in gefitinib-resistant HCC827 GR5 NSCLC cells, MBZ plus gefitinib reduced cell viability substantially more than gefitinib alone and more than low-dose MBZ alone.
  • Primary in vivo efficacy finding: the gefitinib + MBZ combination suppressed tumor growth and prolonged tumor doubling time from 6.2 days in controls to 25 days, with reported growth delay of 18.8 days.
  • Important limitations: evidence is preclinical and based on a limited gefitinib-resistant model system, with uncertain generalizability to other lung cancers or to humans.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroTest whether the microtubule-disrupting drug mebendazole (MBZ) can restore/enhance sensitivity to gefitinib in gefitinib-resistant EGFR-mutant NSCLC (HCC827 GR5), reducing viability and improving anti-tumor effect.in vitro drug response (HCC827 GR5)Expand

In plain English

In gefitinib-resistant EGFR-mutant NSCLC cells (HCC827 GR5), the microtubule disruptor mebendazole (MBZ) reduced cell viability in a dose-dependent manner and, when combined with gefitinib (gefitinib 1 µM + MBZ 0.1 µM), produced substantially greater viability loss than gefitinib alone, consistent with restored/enhanced sensitivity in this resistant in vitro model.

Key findings

  • Gefitinib alone produced minimal cytotoxicity in HCC827 GR5 cells (viability 92.7 ± 1.5%), whereas MBZ alone reduced viability to 79.7 ± 0.6% at 0.1 µM and 29.7 ± 0.6% at 0.5 µM (p < 0.001). Combination treatment (gefitinib 1 µM + MBZ 0.1 µM) further reduced viability to 37.7 ± 0.6% (p < 0.001).Viability: gefitinib 92.7 ± 1.5%; MBZ 79.7 ± 0.6% (0.1 µM) and 29.7 ± 0.6% (0.5 µM); combination 37.7 ± 0.6% (gefitinib 1 µM + MBZ 0.1 µM).
“restore sensitivity to gefitinib in gefitinib-resistant HCC827 GR5 cells”
What this piece can’t prove
  • Abstract does not specify the exact cell viability assay, number of replicates, or full methodological details.

2 further details could not be confirmed from the summary.

2in vitroDefine the mechanism of the MBZ+gefitinib interaction as replication-associated cellular stress/DNA damage (single- and double-strand breaks; γ-H2AX activation).in vitro DNA damage assays (HCC827 GR5)Expand

In plain English

In gefitinib-resistant HCC827 GR5 cells, combination treatment with mebendazole (MBZ) and gefitinib increased markers of replication-associated DNA damage relative to controls: alkaline comet assay showed increased single-strand/alkali-labile damage (tail intensity 22.33 ± 0.56%, p < 0.001), neutral comet assay indicated elevated double-strand breaks, and MBZ produced a dose-dependent increase in γ-H2AX signaling (p < 0.001). The authors interpret these readouts as evidence that MBZ (± gefitinib) induces replication stress–associated DNA damage signaling in this model.

Key findings

  • Alkaline comet assay detected significantly increased single-strand/alkali-labile DNA damage in the combination (MBZ + gefitinib) group.tail intensity 22.33 ± 0.56% (p < 0.001)
  • Neutral comet assay showed elevated double-strand DNA breaks with combination treatment.
“alkaline comet assay revealed significantly increased single-strand DNA damage”
What this piece can’t prove
  • Abstract lacks methodological detail (assay conditions, number of replicates, statistical tests) and does not specify the modality used for γ-H2AX measurement.
  • Numeric results are partially reported (some effect sizes missing), limiting assessment of magnitude for some endpoints (neutral comet).

1 further detail could not be confirmed from the summary.

3in vivo animalDemonstrate in vivo anti-tumor efficacy and tolerability of the combination therapy in a tumor model, including tumor growth suppression/doubling time and systemic toxicity assessment.in vivo animalExpand

In plain English

In an in vivo tumor study, the gefitinib + mebendazole combination significantly suppressed tumor growth versus control, increasing tumor doubling time from 6.2 days to 25 days and producing a growth delay of 18.8 days (p < 0.01). The authors report this antitumor effect occurred without substantial systemic toxicity.

Key findings

  • Gefitinib + MBZ combination significantly suppressed tumor growth compared with control, prolonging tumor doubling time from 6.2 days to 25 days and producing a growth delay of 18.8 days (p < 0.01).Doubling time: 6.2 → 25 days; growth delay: 18.8 days (p < 0.01)
  • Combination therapy was reported to produce antitumor effects without substantial systemic toxicity.
“In vivo, combination therapy significantly suppressed tumor growth”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

SelectedOpen access

Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer

PloS One · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
CandidateOpen access

Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell lines.

PloS One · 2025 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.